AMICUS THERAPEUTICS INC

Form 4 March 24, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** Form 5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person *

Baird William D III

(First) (Middle)

1 CEDAR BROOK DRIVE

(Street)

2. Issuer Name and Ticker or Trading

Symbol

AMICUS THERAPEUTICS INC [FOLD]

3. Date of Earliest Transaction (Month/Day/Year)

03/20/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 0.5

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner _X__ Officer (give title Other (specify below)

Chief Financial Officer

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

	CRAN	BUI	KΥ,	NJ	085	12
--	------	-----	-----	----	-----	----

(City)	(State)	(Zip) Tab	le I - Non-l	Derivative	Secur	ities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit onor Dispos (Instr. 3, 4	ed of	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	03/20/2015		M <u>(1)</u>	5,080	A	\$ 11.506 (2)	105,080	D	
Common stock	03/20/2015		M(1)	2,655	A	\$ 11.506 (2)	107,735	D	
Common stock	03/20/2015		M(1)	7,500	A	\$ 11.506 (2)	115,235	D	
Common stock	03/20/2015		S(1)	15,235	D	\$ 11.506	100,000	D	

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerci Expiration Da (Month/Day/Y	te	7. Title and Underlying (Instr. 3 and	Securities 1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	\$ 3.53	03/20/2015		M <u>(1)</u>	5,080	01/28/2014	01/28/2023	Common Stock	5,080
Stock Options (right to buy)	\$ 2.52	03/20/2015		M(1)	2,655	06/18/2014	06/18/2023	Common stock	2,655
Stock options (right to buy)	\$ 2.45	03/20/2015		M(1)	7,500	01/03/2015	01/03/2024	Common stock	7,500

Reporting Owners

Reporting Owner Name / Address	Relationships						
Troporous o water tumo, rauntess	Director	10% Owner	Officer	Other			
Baird William D III							
1 CEDAR BROOK DRIVE			Chief Financial Officer				
CRANBURY, NJ 08512							

Reporting Owners 2

Signatures

/s/ William D. Baird, III

03/24/2015

**Signature of Reporting

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.17 to \$11.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line (3) range from \$11.17 to \$11.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3